Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Gross Profit Margin for the year ending December 31, 2023

Iterum Therapeutics PLC Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Margin represents the percentage of revenue that represents gross profit, indicating the efficiency of a company's production and pricing.
  • Iterum Therapeutics PLC Gross Profit Margin for the year ending December 31, 2019 was 100.00%, a 0.00% change year over year.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email